Bone marrow analysis with cytogenetics (karyotype, with or without fluorescence in situ hybridization [FISH]) is necessary for stratifying and to guide therapy of AML.1
The bone marrow biopsy provides insight into the2:
- Degree of disease involvement
- Specific histologic features associated with the leukemic process (eg, necrosis, fibrosis)
The aspirate provides material to determine2:
- Blast cell count and ratio of myeloid to erythroid precursors (M:E)
- Cytologic evaluation of the blasts and other cells that may be residual normal hematopoietic elements or abnormal cells maturing from the blasts
1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.1.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed January 29, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. Orazi A. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. Pathobiology. 2007;74(2):97-114.